High incidence of chromosomal abnormalities at 1p36 and 9p21 in early-stage central type squamous cell carcinoma and squamos dysplasia of bronchus detected by autoflourescence bronchoscopy

Oncology Reports

Volumn 22, Issue 1, 2009, Pages 81-87

  Shibukawa, Kiyoko ^a   Miyokawa, Naoyuki ^a   Tokusashi, Yoshihiko ^a   Sasaki, Takaaki ^a   Osanai, Shinobu ^a   Ohsaki, Yoshinobu ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Autofluorescence bronchospy; Loss of heterozygosity; Microsatellite instability; P16; P73; Squamous cell carcinoma; Squamous dysplasia

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53; PROTEIN P73;

AGED; ARTICLE; AUTOFLUORESCENCE IMAGING; BRONCHOSCOPY; BRONCHUS MUCOSA; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CHROMOSOME 1P; CHROMOSOME 9P; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY CANCER; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG CARCINOGENESIS; LUNG DYSPLASIA; LUNG SQUAMOUS CELL CARCINOMA; MALE; MICROSATELLITE INSTABILITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; BRONCHOSCOPY; CARCINOMA, BRONCHOGENIC; CARCINOMA, SQUAMOUS CELL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA-BINDING PROTEINS; EARLY DETECTION OF CANCER; FLUORESCENCE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 68249157092     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000409     Document Type: Article

References (56)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Goya T, Asamura H, Yoshimura H, et al: Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 50: 227-234, 2005.
3. Yang P, Allen MS, Aubry MC, et al: Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 128: 452-462, 2005.
4. Devesa SS, Bray F, Vizcaino AP and Parkin DM: International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117: 294-299, 2005.
5. American Thoracic Society: Cigarette smoking and health. Am J Respir Crit Care Med 153: 861-865, 1996.
6. Wakai K, Inoue M, Mizoue T, Tanaka K, Tsuji I, Nagata C and Tsugane S: Tobacco smoking and lung cancer risk: an evaluation based on a systematic review of epidemiological evidence among the Japanese population. Jpn J Clin Oncol 36: 309-324, 2006.
7. Cortese DA, Edell ES and Kinsey JH: Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin Proc 72: 595-602, 1997.
8. Furuse K, Fukuoka M, Kato H, et al: A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group. J Clin Oncol 11: 1852-1857, 1993.
9. Lam S: Photodynamic therapy of lung cancer. Semin Oncol 21 (Suppl. 15): S15-S19, 1994.
10. Auerbach O and Garfinkel L: The changing pattern of lung carcinoma. Cancer 68: 1973-1977, 1991.
11. Sato M, Saito Y, Usuda K, Takahashi S, Sagawa M and Fujimura S: Occult lung cancer beyond bronchoscopic visibility in sputum-cytology positive patients. Lung Cancer 20: 17-24, 1998.
12. Kennedy TC, Lam S and Hirsch FR: Review of recent advances in fluorescence bronchoscopy in early localization of central airway lung cancer. Oncologist 6: 257-262, 2001.
13. Kusunoki Y, Imamura F, Uda H, Mano M and Horai T: Early detection of lung cancer with laser-induced fluorescence endoscopy and spectrofluorometry. Chest 118: 1776-1782, 2000.
14. Lam S, Kennedy T, Unger M, et al: Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 113: 696-702, 1998.
15. Lam S, MacAulay C, Le Riche JC and Palcic B: Detection and localization of early lung cancer by fluorescence bronchoscopy. Cancer 89 (Suppl. 11): S2468-S2473, 2000.
16. O'Neil KM and Johnson BE: Lights flicker on fluorescence bronchoscopy in patients at risk for lung cancer. J Natl Cancer Inst 90: 953-955, 1998.
17. Palcic B, Lam S, Hung J and MacAulay C: Detection and localization of early lung cancer by imaging techniques. Chest 99: 742-743, 1991.
18. Chiyo M, Shibuya K, Hoshino H, et al: Effective detection of bronchial preinvasive lesions by a new autofluorescence imaging bronchovideoscope system. Lung Cancer 48: 307-313, 2005.
19. Ohsaki Y, Nishigaki Y, Takeyama K, et al: Visualization of cancer using high sensitive fluorodynamic camera and fiber-optic endoscope. Porphyrins 9: 197-203, 2000.
20. Ohsaki Y, Takeyama K, Nakao S, et al: Detection of photofrin fluorescence from malignant and premalignant lesions in the bronchus using a full-color endscopic fluorescence imaging system: a preliminary report. Diagn Ther Endosc 7: 187-195, 2001.
21. Nakanishi K, Ohsaki Y, Kurihara M, et al: Color autofluorescence from cancer lesions: improved detection of central type lung cancer. Lung Cancer 58: 214-219, 2007.
22. Kohno T, Takahashi M, Manda R and Yokota J: Inactivation of the PTEN/ MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 22: 152-156, 1998.
23. Niklinski J, Niklinska W, Chyczewski L, Becker HD and Pluygers E: Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications. Eur J Cancer Prev 10: 213-226, 2001.
24. Smith ML, Chen IT, Zhan Q, et al: Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266: 1376-1380, 1994.
25. Zochbauer-Muller S, Gazdar AF and Minna JD: Molecular pathogenesis of lung cancer. Annu Rev Physiol 64: 681-708, 2002.
26. Brennan JA, Boyle JO, Koch WM, et al: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 332: 712-717, 1995.
27. Denissenko MF, Pao A, Tang M and Pfeifer GP: Preferential formation of benzo[α]pyrene adducts at lung cancer mutational hotspots in P53. Science 274: 430-432, 1996.
28. Negrini M, Monaco C, Vorechovsky I, et al: The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 56: 3173-3179, 1996.
29. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994.
30. Pan H, Califano J, Ponte JF, et al: Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res 65: 1664-1669, 2005.
31. Yoshino I, Osoegawa A, Yohena T, Kameyama T, Oki E, Oda S and Maehara Y: Loss of heterozygosity (LOH) in non-small cell lung cancer: difference between adenocarcinoma and squamous cell carcinoma. Respir Med 99: 308-312, 2005.
32. Kawakami Y and Ogura S: The outline of the general rule for clinical and pathological record of lung cancer. Nippon Rinsho 58: 999-1004, 2000.
33. Cawkwell L, Bell SM, Lewis FA, Dixon MF, Taylor GR and Quirke P: Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer 67: 1262-1267, 1993.
34. Erill N, Colomer A, Calvo M, et al: A novel multiplexing, polymerase chain reaction-based assay for the analysis of chromosome 18q status in colorectal cancer. J Mol Diagn 7: 478-485, 2005.
35. Shibata N, Watari J, Fujiya M, Tanno S, Saitoh Y and Kohgo Y: Cell kinetics and genetic instabilities in differentiated type early gastric cancers with different mucin phenotype. Hum Pathol 34: 32-40, 2003.
36. Brown DC and Gatter KC: Ki67 protein: the immaculate deception? Histopathology 40: 2-11, 2002.
37. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998.
38. Kaghad M, Bonnet H, Yang A, et al: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819, 1997.
39. Okamoto A, Demetrick DJ, Spillare EA, et al: Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91: 11045-11049, 1994.
40. Trink B, Okami K, Wu L, Sriuranpong V, Jen J and Sidransky D: A new human p53 homologue. Nat Med 4: 747-748, 1998.
41. Jost CA, Marin MC and Kaelin WG Jr: p73 is a simian (correction of human) p53-related protein that can induce apoptosis. Nature 389: 191-194, 1997.
42. Ozaki T and Nakagawara A: p73, a sophisticated p53 family member in the cancer world. Cancer Sci 96: 729-737, 2005.
43. Tannock I (ed): The Basic Science of Oncology. 4th edition. McGraw-Hill, New York, 2005.
44. De Laurenzi V, Costanzo A, Barcaroli D, et al: Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 188: 1763-1768, 1998.
45. Ueda Y, Hijikata M, Takagi S, Chiba T and Shimotohno K: New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene 18: 4993-4998, 1999.
46. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR and Miller FD: An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289: 304-306, 2000.
47. Stiewe T, Zimmermann S, Frilling A, Esche H and Putzer BM: Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res 62: 3598-3602, 2002.
48. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T, Takahashi T and Takahashi T: Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 58: 1380-1383, 1998.
49. Sharpless NE, Bardeesy N, Lee KH, et al: Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413: 86-91, 2001.
50. Kishimoto Y, Sugio K, Hung JY, Virmani AK, McIntire DD, Minna JD and Gazdar AF: Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small cell lung cancers. J Natl Cancer Inst 87: 1224-1229, 1995.
51. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA and Geradts J: Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 56: 3415-3420, 1996.
52. Sakaguchi M, Fujii Y, Hirabayashi H, et al: Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer 65: 442-445, 1996.
53. Taga S, Osaki T, Ohgami A, et al: Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma. Cancer 80: 389-395, 1997.
54. Marsit CJ, Wiencke JK, Nelson HH, Kim DH, Hinds PW, Aldape K and Kelsey KT: Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, TP53, and survival. Cancer Genet Cytogenet 162: 115-121, 2005.
55. Zienolddiny S, Ryberg D, Arab MO, Skaug V and Haugen A: Loss of heterozygosity is related to p53 mutations and smoking in lung cancer. Br J Cancer 84: 226-231, 2001.
56. Brambilla E, Gazzeri S, Moro D, Lantuejoul S, Veyrenc S and Brambilla C: Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 5: 243-250, 1999.